CEO Talat Imran Acquires Additional Shares of Rani Therapeutics Holdings Inc
RANI Stock | USD 1.82 0.04 2.15% |
Under 61% of Rani Therapeutics' investor base is looking to short. The analysis of the overall investor sentiment regarding Rani Therapeutics Holdings suggests that many traders are alarmed. Rani Therapeutics' investing sentiment shows overall attitude of investors towards Rani Therapeutics Holdings.
Rani |
On December 9, 2024, Talat Imran, the CEO of Rani Therapeutics Holdings Inc , purchased 10,296 shares of the company. Following this transaction, the insi
Read at gurufocus.com
Rani Therapeutics Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards Rani Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
RANI: 1Q:24 Results
recently @ finance.yahoo.com
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Rani Therapeutics Fundamental Analysis
We analyze Rani Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Rani Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Rani Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Return On Equity
Return On Equity Comparative Analysis
Rani Therapeutics is currently under evaluation in return on equity category among its peers. Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Rani Therapeutics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Rani Therapeutics stock to make a market-neutral strategy. Peer analysis of Rani Therapeutics could also be used in its relative valuation, which is a method of valuing Rani Therapeutics by comparing valuation metrics with similar companies.
Peers
Rani Therapeutics Related Equities
TRVI | Trevi Therapeutics | 61.04 | ||||
PHVS | Pharvaris | 6.07 | ||||
VIRX | Viracta Therapeutics | 5.88 | ||||
PMVP | Pmv Pharmaceuticals | 3.82 | ||||
VCNX | Vaccinex | 3.01 | ||||
MNPR | Monopar Therapeutics | 1.24 | ||||
CRVS | Corvus Pharmaceuticals | 0.49 | ||||
CABA | Cabaletta Bio | 0.65 | ||||
SRZN | Surrozen | 0.75 | ||||
TARA | Protara Therapeutics | 0.96 | ||||
MOLN | Molecular Partners | 2.13 | ||||
VINC | Vincerx Pharma | 2.52 | ||||
TYRA | Tyra Biosciences | 2.88 | ||||
LYRA | Lyra Therapeutics | 3.62 | ||||
BMEA | Biomea Fusion | 3.91 | ||||
EYPT | Eyepoint Pharmaceuticals | 4.24 | ||||
ALXO | Alx Oncology | 4.64 | ||||
GLUE | Monte Rosa | 9.52 | ||||
TNYA | Tenaya Therapeutics | 24.02 |
Complementary Tools for Rani Stock analysis
When running Rani Therapeutics' price analysis, check to measure Rani Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Rani Therapeutics is operating at the current time. Most of Rani Therapeutics' value examination focuses on studying past and present price action to predict the probability of Rani Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Rani Therapeutics' price. Additionally, you may evaluate how the addition of Rani Therapeutics to your portfolios can decrease your overall portfolio volatility.
Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
Transaction History View history of all your transactions and understand their impact on performance | |
Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
Content Syndication Quickly integrate customizable finance content to your own investment portal | |
Share Portfolio Track or share privately all of your investments from the convenience of any device | |
Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments |